Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 5, 2025, and July 23, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that defendants made false statements and concealed material adverse facts regarding the company's medical cost trend assumptions [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical cost trends, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - The lawsuit suggests that Molina's near-term growth relied on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services, which misled investors about the company's business prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Stock Impact - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Shareholders who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones involves significant challenges and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score simplifies the process of identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Progyny (PGNY) is currently highlighted as a recommended growth stock, featuring a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly desirable as it indicates strong future prospects [4] - Progyny has a historical EPS growth rate of 15.2%, but projected EPS growth for this year is expected to be 500%, significantly surpassing the industry average of 14.6% [5] Group 3: Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for assessing efficiency in growth investing [6] - Progyny's S/TA ratio stands at 1.75, indicating that the company generates $1.75 in sales for every dollar in assets, compared to the industry average of 0.76 [6] Group 4: Sales Growth - Sales growth is another key indicator, with Progyny expected to achieve a sales growth rate of 9.2% this year, while the industry average is projected at 0% [7] Group 5: Earnings Estimate Revisions - Trends in earnings estimate revisions are correlated with stock price movements, making them a valuable indicator for investors [8] - Progyny's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 8% over the past month [9] Group 6: Overall Positioning - Progyny has achieved a Zacks Rank of 2 due to positive earnings estimate revisions and has earned a Growth Score of A based on several favorable metrics [11] - This combination positions Progyny well for potential outperformance, making it an attractive option for growth investors [11]

Group 1: Stock Performance and Rankings - Pediatrix Medical Group, Inc. (MD) has a Zacks Rank 1 and its earnings estimate increased by 15.7% over the last 60 days [1] - Pediatrix's shares gained 35.4% over the last three months, significantly outperforming the S&P 500's 2.9% increase [2] - La-Z-Boy Incorporated (LZB) also holds a Zacks Rank 1 with a 3.2% increase in its earnings estimate over the last 60 days [2] - La-Z-Boy's shares increased by 3% over the last three months, matching the S&P 500's performance [2] - Grupo Cibest S.A. (CIB) has a Zacks Rank 1 and its earnings estimate rose by 8.7% over the last 60 days [3] - Grupo Cibest's shares increased by 22.1% over the last three months, again outperforming the S&P 500 [3] Group 2: Momentum Scores - Pediatrix Medical Group possesses a Momentum Score of A, indicating strong momentum characteristics [2] - La-Z-Boy has a Momentum Score of B, reflecting moderate momentum [2] - Grupo Cibest also holds a Momentum Score of B, suggesting a similar level of momentum as La-Z-Boy [3]

Core Insights - Wall Street experienced a rebound on November 21, 2025, with all three major stock indices rising nearly 1% due to investor optimism about a potential rate cut in December following dovish comments from John Williams, president of the Federal Reserve Bank of New York [1] Market Conditions - Despite the rebound, concerns over overvalued AI stocks persist, which could lead to a sell-off in the broader market at any time [2] Investment Strategy - In the current unstable environment, equity investors are advised to avoid high-priced stocks and consider dividend-growth stocks, as these companies typically exhibit strong financial health and provide a defensive hedge against economic uncertainty [3][5] - Dividend-growth stocks are characterized by a history of increasing dividends, which offers downside protection and potential for capital appreciation [5][6] Selected Dividend Growth Stocks - Five dividend growth stocks identified as solid choices include: - **Cardinal Health (CAH)**: Expected fiscal 2026 revenue growth of 16.2%, long-term earnings growth rate of 13.9%, and an annual dividend yield of 0.98% [12][13] - **Barrick Mining (B)**: Projected 2025 revenue growth of 21.5%, long-term earnings growth rate of 38.4%, and an annual dividend yield of 1.64% [14] - **NetEase (NTES)**: Anticipated 2025 revenue growth of 10.4%, long-term earnings growth rate of 9.9%, and an annual dividend yield of 1.70% [15] - **Lam Research (LRCX)**: Expected fiscal 2026 revenue growth of 14.1%, long-term earnings growth rate of 20.3%, and an annual dividend yield of 0.73% [16] - **Enersys (ENS)**: Projected fiscal 2026 revenue growth of 4%, long-term earnings growth rate of 15%, and an annual dividend yield of 0.76% [17] Selection Criteria - The selection of these stocks is based on criteria such as multi-year growth in dividends, sales, earnings per share (EPS), and undervaluation metrics [10][11] - Stocks selected have shown historical growth in dividends, sales, and EPS, indicating strong fundamentals and potential for sustained dividend payments [8][9]

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH). Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/ ...

Group 1 - Amer Sports, Inc. has seen a Zacks Consensus Estimate increase of 8.3% for its current year earnings over the last 60 days [1] - Intuitive Surgical, Inc. has experienced a 5.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Pediatrix Medical Group, Inc. has had a significant increase of 15.7% in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Seanergy Maritime Holdings Corp. has seen a remarkable 66.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Grupo Cibest S.A. has experienced an 8.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price, which fell over 33% after the company reported disappointing Q3 2025 financial results [1][3][4]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue due to "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million, citing "adverse prior period claim developments" from claims between 2019 and 2022, as well as broader industry trends [4]. Investigation Details - The investigation focuses on Ardent's accounting practices, particularly regarding accounts receivable and professional liability reserves [3]. - Bleichmar Fonti & Auld LLP, a leading securities law firm, is conducting the investigation and has urged investors to come forward [1][5].

Core Insights - Three stocks are highlighted with a buy rank and strong value characteristics for investors to consider on November 24 Group 1: John B. Sanfilippo & Son, Inc. (JBSS) - The company operates in the tree nuts and peanuts sector and holds a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 7.8% over the last 60 days [1] - The price-to-earnings ratio (P/E) is 11.84, significantly lower than the industry average of 29.50 [1] - The company has a Value Score of A [1] Group 2: Grupo Cibest S.A. (CIB) - This company provides banking services and products and also holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 8.7% over the last 60 days [2] - The price-to-earnings ratio (P/E) is 7.81, compared to 24.24 for the S&P 500 [2] - The company has a Value Score of B [2] Group 3: Pediatrix Medical Group, Inc. (MD) - The company specializes in newborn care, maternal-fetal medicine, and pediatric subspecialty services, holding a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 15.7% over the last 60 days [3] - The price-to-earnings ratio (P/E) is 11.19, lower than the S&P 500 average of 24.24 [3] - The company has a Value Score of B [3]